Marshall Wace’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Marshall Wace’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-574,050	Closed	-$5.71M	–	4451
2021 Q3	$5.71M	Buy	574,050 +23,862	+4%	+$236K	0.02%	867
2021 Q2	$5.44M	Buy	+550,188	New	+$5.4M	0.02%	791

Other funds holding PEAR

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SGA

SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return

Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return

TAA

TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Marshall Wace's PEAR Position: Q4 2021 in Review

Marshall Wace sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2021, closing a stake of 574,050 shares — an estimated $5.71M sold.

Marshall Wace first reported a position in PEAR in Q2 2021 and held it in 2 quarters. The position peaked at $5.71M in Q3 2021. 25 funds tracked by Wall St. Rank hold PEAR as of Q4 2021.

Marshall Wace reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
Marshall Wace sold 574,050 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2021, an estimated $5.71M.
Marshall Wace first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 2 quarters.
Marshall Wace's Pear Therapeutics, Inc. Class A Common Stock position peaked at $5.71M in Q3 2021.
25 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.